Early this week, I had the privilege of watching my boss, Dr. Flavia Matovu Kiweewa
deliver a 1-minute elevator pitch to the President during his visit to our exhibition stall at the Makerere University Research and Innovation Week that’s been running since Tuesday.
She spoke with clarity and conviction about the PURPOSE 1 study—a groundbreaking trial on Lenacapavir, the twice-yearly injectable for HIV prevention (PrEP).